Enurex Solution

• Central diabetes insipidus
• Primary nocturnal enuresis (bed-wetting)
• Nocturia (nocturnal polyuria)
• Hemophilia A and von Willebrand disease (Type I)

Desmopressin mimics the actions of endogenous ADH and acts as a selective agonist of V2 receptors expressed in the renal collecting duct to increase water re-absorption and reduce urine production. Desmopressin has been shown to be more potent than ADH in increasing plasma levels of factor VIII activity in patients with hemophilia and von Willebrand's disease Type I. Desmopressin demonstrates markedly diminished pressor activity.

Adult - Diabetes Insipidus (PO): 0.05 mg every 12 hours; effective range 0.1-1.2 mg/day divided 8-12 hourly.
Adult - Diabetes Insipidus (Intranasal): 10-40 mcg/day (usually 20 mcg/day in 2 divided doses).
Adult - Nocturia (Sublingual): Women: 27.7 mcg/day; Men: 55.3 mcg/day, 1 hour before bedtime.
Child - Bed-wetting (>6 years): 0.2 mg PO at night (max 0.6 mg/day).
Hemophilia A/von Willebrand: 0.3 mcg/kg IV (30 min before procedure).

Common: Headache, nausea, stomach pain.
Rare (high doses): Transient headache, nausea, flushing, mild abdominal cramps, decreased sodium levels (hyponatremia), water intoxication.

Desmopressin is generally considered safe during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.

Fluid restriction is recommended (to prevent water intoxication and hyponatremia). Monitor sodium levels regularly. Do not use in patients with hyponatremia or history of hyponatremia. Caution in coronary artery insufficiency and hypertensive cardiovascular disease.

Overdose may lead to water intoxication and hyponatremia. Seek medical attention.

Store at temperature not exceeding 30°C in a dry place. Protect from light and moisture.